Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04936464
Other study ID # 12791
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 20, 2021
Est. completion date June 30, 2024

Study information

Verified date October 2023
Source Kaiser Permanente
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, double-blinded, randomized controlled trial evaluating the efficacy of TTNS versus a sham intervention. Both interventions will be performed by participants in their homes after standardized instruction. The primary outcome is a comparison of the mean change in OAB-q scores before and after treatment between the intervention and control groups. Changes in the number of urgency incontinence episodes and an estimation of cost effectiveness will additionally be measured. Intention to treat analysis will be performed.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 99
Est. completion date June 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - = 6 episodes urgency incontinence on 3-day voiding diary - Duration of symptoms = 3 months - Off antimuscarinic or 3-adrenoreceptor agonist therapy for 2 weeks - No known neurologic disease - Ability to complete home sessions and clinic follow up - Ability to complete voiding diaries - Internet access and proficiency - English or Spanish-speaking Exclusion Criteria: - Pregnant - Known or suspected urinary retention - Symptomatic urinary tract infection unresolved at the time of randomization - Recurrent urinary tract infection (= 3/12 months) - Bladder pain syndrome - Known or suspected advanced (stage III or IV) pelvic organ prolapse - Neurogenic bladder - Current or prior bladder malignancy - Current or previous use of bladder Botox injections, percutaneous tibial nerve stimulation, or sacral neuromodulation - Pacemaker or other implantable device - Disease affecting lower extremities - Bilateral metallic lower limb implant - Incarceration

Study Design


Intervention

Device:
transcutaneous tibial nerve stimulation (TTNS)
TTNS is a non-invasive, surface electrode therapeutic stimulation technique available for home administration that has been proposed as a treatment for overactive bladder.
transcutaneous electrical stimulation (TENS)
The sham intervention is designed to appear almost identical to the TTNS intervention.

Locations

Country Name City State
United States Kaiser Permanente San Diego San Diego California

Sponsors (2)

Lead Sponsor Collaborator
Kaiser Permanente American Urogynecologic Society

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Incremental cost-effectiveness ratio (ICER) To describe the cost effectiveness of a 12-week course of home-based TTNS therapy using an ICER calculated from the sum of direct medical and indirect non-medical costs relative to health-related quality of life, as measured by the European Quality of Life-5 Dimensions index. 12 weeks
Primary Overactive Bladder Questionnaire (OAB-q) To evaluate the efficacy of a 12-week course of TTNS in reducing urgency urinary incontinence (UUI) symptom bother in the intervention versus sham group. 12 weeks
Secondary Voiding diary To evaluate the efficacy of a 12-week course of TTNS in reducing the frequency of UUI episodes in the intervention versus sham group. 12 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT04578899 - "The Effectiveness of Transvertebral Magnetic Neuromodulation in Patients With Detrusor Overactivity" N/A
Active, not recruiting NCT03556891 - Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence N/A
Not yet recruiting NCT05977634 - Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder N/A
Completed NCT01955408 - Severity of Overactive Bladder Symptoms in Patients After Synergo Treatment N/A
Recruiting NCT06201013 - Efficacy and Safety of Vitamin D in the Treatment of OAB-wet in Children N/A
Recruiting NCT03727711 - TPTNS: Home vs Hospital Treatment for Overactive Bladder N/A
Completed NCT00768521 - A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107) Phase 1
Completed NCT03625843 - Mindfulness Exercises to Reduce Anxiety and Pain During Urodynamic Testing N/A
Completed NCT02211846 - A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder Phase 1
Completed NCT02835846 - Investigation of the Effect of the Female Urinary Microbiome on Incontinence Phase 4
Completed NCT02857816 - PRospective Study to Evaluate EffectivenesS With the NURO™ PErcutaneous Tibial Neuromodulation System in Patients With OAB N/A
Withdrawn NCT02320201 - Foot Neuromodulation for Overactive Bladder in Children N/A
Completed NCT02202031 - Controlling Urgency Through Relaxation Exercises N/A
Not yet recruiting NCT01423838 - Comparison of Solifenacin and Oxybutynin in the Treatment of Overactive Bladder Phase 4
Not yet recruiting NCT01409512 - Evaluation of Autonomic System Before and After Anticholinergic Treatment in Women With Overactive Bladder N/A
Completed NCT01437670 - Observational Study to Estimate the Dry Mouth in OAB Patients With Solifenacin N/A
Completed NCT01458197 - A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder. Phase 2
Terminated NCT01758848 - Physical Therapy for Overactive Bladder N/A
Withdrawn NCT01210859 - Effects of Antimuscarinic Drugs on Overactive Bladder (OAB) Symptoms After Insertion of Ureteral Stents N/A
Terminated NCT01003249 - Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen Phase 4